GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (ASX:ATH) » Definitions » Net Change in Cash

Alterity Therapeutics (ASX:ATH) Net Change in Cash : A$2.58 Mil (TTM As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Alterity Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Alterity Therapeutics's Net Change in Cash for the three months ended in Dec. 2023 was A$-4.39 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was A$2.58 Mil.

Alterity Therapeutics Net Change in Cash Historical Data

The historical data trend for Alterity Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics Net Change in Cash Chart

Alterity Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.84 -5.20 18.92 6.69 -19.03

Alterity Therapeutics Quarterly Data
Jun18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.41 0.05 0.94 -4.39 5.98

Alterity Therapeutics Net Change in Cash Calculation

Alterity Therapeutics's Net Change in Cash for the fiscal year that ended in Jun. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-20.036+-0.036+0.124+0.915
=-19.03

Alterity Therapeutics's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-4.862+-0.001+0.97+-0.495
=-4.39

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was A$2.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Alterity Therapeutics (ASX:ATH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (ASX:ATH) » Definitions » Net Change in Cash
Comparable Companies
ASX:NOX ASX:IMC ASX:ACR ASX:CHM ASX:1AI ASX:ATX ASX:PTX ASX:PAB ASX:RAD ASX:BTC OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
ATHE:USA PBN:Germany
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Website
https://www.alteritytherapeutics.com
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.